Kendall Law Group, led by former federal judge Joe Kendall, is investigating IntegraMed America, Inc. (NASDAQ: INMD) for shareholders in connection with the proposed acquisition by Sagard Capital Partners. The national securities firm’s investigation seeks to determine whether IntegraMed and its Board breached their fiduciary duties by entering into the agreement without properly shopping for a deal that would provide better value for shareholders. If you are an IntegraMed shareholder and would like additional information about your rights, contact the Kendall Law Group at 877-744-3728 or by email at email@example.com. On June 11, 2012, IntegraMed announced the definitive merger agreement under which the company would be acquired by Sagard Capital Partners, in a transaction valued at approximately $169.5 million. Under the terms of the agreement, IntegraMed stockholders will receive $14.05 in cash for each share of IntegraMed/INMD common stock held. The offer represents a 24 percent premium to IntegraMed stock's Friday close. According to Thompson/First Call, analysts have set price targets as high as $17.00 per share for IntegraMed’s stock. The firm’s investigation seeks to determine whether IntegraMed and its Board undertook a fair process in negotiating the deal. Kendall Law Group was founded by a former federal judge, includes a former United States Attorney, prosecutors and securities lawyers who are experienced in complex securities litigation. The firm has been counsel in numerous merger and acquisition cases nationwide, including some of the largest transactions in the United States.
Shares of IntegraMed America (Nasdaq:INMD) have taken a tremendous swing upward. The stock is trading at $13.71 as of 9:55 a.m. ET, 20.9% above Friday's closing price of $11.34. Volume is at 476,658, 22.5 times the daily average of 21,200.